$615.80 Million in Sales Expected for PerkinElmer, Inc. (PKI) This Quarter

Equities research analysts expect that PerkinElmer, Inc. (NYSE:PKI) will post $615.80 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for PerkinElmer’s earnings. The lowest sales estimate is $613.15 million and the highest is $619.70 million. PerkinElmer reported sales of $566.77 million in the same quarter last year, which indicates a positive year over year growth rate of 8.7%. The firm is scheduled to announce its next quarterly earnings results on Thursday, February 1st.

According to Zacks, analysts expect that PerkinElmer will report full year sales of $615.80 million for the current financial year, with estimates ranging from $2.23 billion to $2.24 billion. For the next fiscal year, analysts expect that the business will report sales of $2.42 billion per share, with estimates ranging from $2.33 billion to $2.70 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow PerkinElmer.

PKI has been the subject of several research analyst reports. Robert W. Baird lifted their price objective on shares of PerkinElmer from $75.00 to $78.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. Morgan Stanley lifted their price objective on shares of PerkinElmer from $77.00 to $78.00 and gave the company an “overweight” rating in a research note on Friday, November 3rd. Jefferies Group reiterated a “hold” rating and issued a $70.00 price objective on shares of PerkinElmer in a research note on Friday, October 20th. Goldman Sachs Group reiterated a “neutral” rating and issued a $67.00 price objective on shares of PerkinElmer in a research note on Tuesday, September 26th. Finally, ValuEngine lowered shares of PerkinElmer from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and six have given a buy rating to the company. PerkinElmer currently has an average rating of “Hold” and an average target price of $71.43.

Shares of PerkinElmer (PKI) opened at $76.94 on Friday. The firm has a market cap of $8,450.00, a price-to-earnings ratio of 34.81, a PEG ratio of 1.84 and a beta of 0.77. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.59 and a quick ratio of 2.09. PerkinElmer has a one year low of $50.59 and a one year high of $77.01.

The company also recently announced a quarterly dividend, which will be paid on Friday, February 9th. Stockholders of record on Friday, January 19th will be paid a $0.07 dividend. The ex-dividend date is Thursday, January 18th. This represents a $0.28 annualized dividend and a dividend yield of 0.36%. PerkinElmer’s payout ratio is 12.67%.

In related news, insider Andrew Okun sold 12,680 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $72.00, for a total value of $912,960.00. Following the transaction, the insider now directly owns 25,121 shares of the company’s stock, valued at approximately $1,808,712. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Alexis P. Michas sold 5,000 shares of the business’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $73.18, for a total transaction of $365,900.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 86,336 shares of company stock valued at $6,114,917. Company insiders own 2.20% of the company’s stock.

Large investors have recently modified their holdings of the stock. Ontario Teachers Pension Plan Board boosted its holdings in shares of PerkinElmer by 36.3% in the 2nd quarter. Ontario Teachers Pension Plan Board now owns 95,415 shares of the medical research company’s stock worth $6,502,000 after buying an additional 25,404 shares during the last quarter. Neuberger Berman Group LLC boosted its holdings in shares of PerkinElmer by 59.8% in the 2nd quarter. Neuberger Berman Group LLC now owns 52,030 shares of the medical research company’s stock worth $3,545,000 after buying an additional 19,464 shares during the last quarter. State of Wisconsin Investment Board purchased a new position in shares of PerkinElmer in the 3rd quarter worth about $1,673,000. Bessemer Group Inc. boosted its holdings in shares of PerkinElmer by 22.2% in the 3rd quarter. Bessemer Group Inc. now owns 27,149 shares of the medical research company’s stock worth $1,873,000 after buying an additional 4,936 shares during the last quarter. Finally, Sivik Global Healthcare LLC lifted its holdings in PerkinElmer by 12.5% during the third quarter. Sivik Global Healthcare LLC now owns 90,000 shares of the medical research company’s stock valued at $6,207,000 after purchasing an additional 10,000 shares during the last quarter. 91.37% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://ledgergazette.com/2018/01/13/615-80-million-in-sales-expected-for-perkinelmer-inc-pki-this-quarter-2.html.

About PerkinElmer

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Get a free copy of the Zacks research report on PerkinElmer (PKI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply